-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoPrime Assembly Expands Genome Editing with Precise, Large-Scale DNA Integration
A new genome-editing method, prime assembly, precisely inserts long DNA sequences into targeted genomic locations, potentially enabling mutation-agnostic gene therapies for diverse genetic diseases with fewer...
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoPrime assembly can correct multiple mutations at once, pointing toward universal gene therapies
Genomic editing holds great potential yet continues to have limitations. Current methods either rely on untargeted gene delivery or short DNA edits that need to be...
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoCellares links with GenomeFrontier to test automation approach for virus-free CAR-Ts
Cellares is partnering with Taiwanese biotech GenomeFrontier Therapeutics to evaluate the integrated contract developer and manufacturer’s cell shuttle platform for use in the production of virus-free...
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month ago
Legend Biotech names Novartis veteran Ingrid Zhang as new CEO
Legend Biotech has found its permanent CEO, poaching 15-year Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its next phase of growth.
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month ago
Ori locks down $120M pact to deploy automated production platform for unnamed commercial cell therapy
As a key player in the automated cell therapy manufacturing space grapples with a recent setback, another is making waves with a major commercial pact.
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoCellectis quits CAR-T and pivots to ‘in vivo’ gene editing
Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months ago
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
Cellectis may have kicked off the year promising “huge momentum” in the allogeneic CAR-T space, but even the French biotech has been unable to resist the...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoKaryopharm pushes off debt payment; Amgen eyes broader Imdelltra use
Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agomRNA cancer vaccines’ biggest barriers to market
Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoExegenesis Bio and Modalis sign research deal for Duchenne therapy
The agreement involves the use of Modalis’ CRISPR-GNDM (Guide Nucleotide-Directed Modulation) technology in combination with Exegenesis Bio’s engineered muscle-tropic adeno-associated virus (AAV) capsid, EMC181. EMC181 is...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
